Table 1 Probabilities of OS, PFS, FFS,... | American Society of Hematology

Table 1

Probabilities of OS, PFS, FFS, and MMR at 4 years for patients with >10% BCR-ABL1 at 3 months by univariate analysis of baseline variables and the BCR-ABL1 halving time at 3 months

Variable	No. of evaluable patients	OS (%)	Hazard ratio	Overall P value	PFS (%)	Hazard ratio	Overall P value	FFS (%)	Hazard ratio	Overall P value	MMR (%)	Relative risk	Overall P value
Halving time at 3 months
≤76 days	74	95	1	.002	92	1	.005	59	1	< .0001	54	1	.008
>76 days	21	58	8.80		60	4.78		4.8	6.6		4.7	0.07
Age (median years)
≤48	51	80	1	.09	79	1	.08	43	1	.26	33	1	.16
>48	46	94	0.28		93	0.33		52	0.72		51	1.61
Sex, n (%)
Female	35	97	1	.12	91	1	.41	54	1	.33	46	1	.31
Male	62	82	4.58		84	1.72		44	1.36		39	0.70
Sokal risk group
Low	22	91	1	.77	91	1	.68	58	1	.50	53	1	.51
Intermediate	32	77	0.86		89	1.86		57	1.17		40	0.75
High	40	86	1.49		79	1.12		41	1.55		33	0.62
Assigned imatinib dose
400 mg	25	96	1	.52	92	1	.62	40	1	.43	42	1	.33
600 mg	47	81	3.07		83	1.87		52	0.65		55	1
800 mg	25	86	3.29		82	2.26		50	0.87		25	0.51

Variable	No. of evaluable patients	OS (%)	Hazard ratio	Overall P value	PFS (%)	Hazard ratio	Overall P value	FFS (%)	Hazard ratio	Overall P value	MMR (%)	Relative risk	Overall P value
Halving time at 3 months
≤76 days	74	95	1	.002	92	1	.005	59	1	< .0001	54	1	.008
>76 days	21	58	8.80		60	4.78		4.8	6.6		4.7	0.07
Age (median years)
≤48	51	80	1	.09	79	1	.08	43	1	.26	33	1	.16
>48	46	94	0.28		93	0.33		52	0.72		51	1.61
Sex, n (%)
Female	35	97	1	.12	91	1	.41	54	1	.33	46	1	.31
Male	62	82	4.58		84	1.72		44	1.36		39	0.70
Sokal risk group
Low	22	91	1	.77	91	1	.68	58	1	.50	53	1	.51
Intermediate	32	77	0.86		89	1.86		57	1.17		40	0.75
High	40	86	1.49		79	1.12		41	1.55		33	0.62
Assigned imatinib dose
400 mg	25	96	1	.52	92	1	.62	40	1	.43	42	1	.33
600 mg	47	81	3.07		83	1.87		52	0.65		55	1
800 mg	25	86	3.29		82	2.26		50	0.87		25	0.51